THTX Projected Dividend Yield

Theratechnologies Inc ( NASDAQ : THTX )

Theratechnologies is a biopharmaceutical company focused on the development and commercialization of therapies addressing unmet medical needs. Co. has two approved products: EGRIFTA SV® in the U.S., and Trogarzo® in the U.S., the European Union and the U.K. EGRIFTA SV® is the therapy in the U.S. for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy. Trogarzo® is the HIV treatment. The treatment is infused every two weeks. It is a class of antiretrovirals, or ARV, and is a long-acting ARV therapy that can lead to an undetectable viral load in combination with other ARVs.

20 YEAR PERFORMANCE RESULTS